SCHEDULE: MAK Capital Secures Board Seat at Evotec SE

MAK Capital Fund LP has entered into a cooperation agreement with Evotec SE, resulting in the nomination of Dr. Wolfgang Hofmann to the company's Supervisory Board.

Summary

• MAK Capital Fund LP and its affiliates now beneficially own 12,681,898 shares of Evotec SE, representing a 7.1% stake.
• The reporting persons entered into a cooperation agreement with Evotec SE on April 29, 2026.
• Evotec SE will nominate Dr. Wolfgang Hofmann as an independent member of the Supervisory Board for the upcoming Annual General Meeting (AGM).
• The AGM, scheduled for June 11, 2026, will also vote on increasing the Supervisory Board size from six to seven members.
• MAK Capital has committed to voting in favor of the board expansion and supporting the company's nominated candidates.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a constructive development, as the cooperation agreement signals a collaborative approach to governance rather than a hostile takeover attempt.

Positives

• Active engagement by a significant shareholder (7.1% stake) to improve corporate governance.
• Successful negotiation of a cooperation agreement, reducing potential for proxy conflict.
• Alignment of interests between the investor and the company regarding board composition.

Negatives

• The investor has agreed to customary voting restrictions as part of the cooperation agreement, limiting their independent strategic influence.
• The aggregate purchase price of the stake was approximately 73.3 million euros, representing a significant capital deployment.

Risks

• Potential for future disagreements if the newly appointed board member does not align with the investor's expectations.
• Market volatility affecting the value of the 7.1% stake.
• Dependence on the successful outcome of the June 11, 2026, AGM for the board expansion and nominations.

Future Outlook

The company intends to expand its Supervisory Board from six to seven members and appoint Dr. Wolfgang Hofmann as an independent member, subject to shareholder approval at the June 2026 AGM.

Management Comments

• The reporting persons have agreed to support the company's nominees and the proposed board expansion.

Industry Context

StockSavvy.ai notes that this move reflects a broader trend of activist investors seeking board representation in European biotech firms to drive governance improvements and strategic oversight.

Comparison to Industry Standards

• The 7.1% stake is a significant position, typical of mid-tier activist campaigns in the European life sciences sector.
• The use of a cooperation agreement to avoid a contested proxy fight is a standard and preferred outcome for both management and institutional investors.

Corporate Governance

Stakeholder Impact

• Shareholders benefit from increased board oversight and reduced risk of a proxy battle.
• The company gains a stable relationship with a significant institutional investor.

Next Steps

• Hold the Annual General Meeting on June 11, 2026.
• Vote on the expansion of the Supervisory Board.
• Elect Dr. Wolfgang Hofmann and other nominees to the Supervisory Board.

Key Dates

Recommendation

The stock is likely to see stability following the resolution of potential governance friction, but the long-term value depends on the operational performance of the company under the new board structure.

Keywords

Evotec SE, MAK Capital, Supervisory Board, Corporate Governance, Shareholder Activism, Cooperation Agreement